We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ascendis Submits BLA to FDA for TransConhGH in Pediatric GHD
Read MoreHide Full Article
Ascendis Pharma A/S ((ASND - Free Report) ) announced that it has submitted a Biologics License Application (BLA) to the FDA for TransConhGH (lonapegsomatropin), for the treatment ofpediatric growth hormone deficiency (GHD). TransConhGH is a long-acting, once-weekly prodrug of somatropin (human growth hormone or hGH).
Pediatric GHD is a serious orphan disease, which is caused when the pituitary gland does not produce enough growth hormone.
The TransCon platform is an innovative technology designed to create new therapies that optimize therapeutic effect, including efficacy, safety and dosing frequency. The company believes that the TransContechnology has the potential to address major unmet medical needs. TransConhGH is designed to maintain the same mode of action as daily hGH therapies by releasing the same growth hormone molecule, somatropin. Currently, there is no approved long-acting growth hormone treatment in the United States or Europe. TransConhGH has Orphan Drug designation for GHD in both the United States and Europe.
A potential approval of TransConhGH will enable the company to address the large unmet need and be a potential new treatment option forchildren with GHD.
Ascendis Pharma plans to submit a Marketing Authorization Application (MAA) for TransConhGH to the European Medicines Agency in the third quarter for pediatric GHD. The company also plans to initiate a phase III study with TransConhGH in pediatric GHD in Japan in the fourth quarter and a phase III study is ongoing in Greater China.
Shares of Ascendis have increased 6.4% year to date compared with the industry’s growth of 10.8%.
Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company which aims at making a meaningful difference in patients’ lives.
Zacks Rank &Stocks to Consider
Ascendis currently carries a Zacks Rank #3 (Hold).
Applied Therapeutics’ loss per share estimates have narrowed from $3.02 to $2.73 for 2020 and from $3.41 to $3.28 for 2021 in the past 60 days.
Emergent’s earnings per share estimates have increased from $3.43 to $4.03 for 2020 and from $3.54 to $3.73 for 2021 in the past 60 days.
Ligand Pharmaceuticals’ earnings per share estimates have increased from $3.45 to $3.70 for 2020 and from $4.00 to $4.40 for 2021 in the past 60 days.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Ascendis Submits BLA to FDA for TransConhGH in Pediatric GHD
Ascendis Pharma A/S ((ASND - Free Report) ) announced that it has submitted a Biologics License Application (BLA) to the FDA for TransConhGH (lonapegsomatropin), for the treatment ofpediatric growth hormone deficiency (GHD). TransConhGH is a long-acting, once-weekly prodrug of somatropin (human growth hormone or hGH).
Pediatric GHD is a serious orphan disease, which is caused when the pituitary gland does not produce enough growth hormone.
The TransCon platform is an innovative technology designed to create new therapies that optimize therapeutic effect, including efficacy, safety and dosing frequency. The company believes that the TransContechnology has the potential to address major unmet medical needs. TransConhGH is designed to maintain the same mode of action as daily hGH therapies by releasing the same growth hormone molecule, somatropin. Currently, there is no approved long-acting growth hormone treatment in the United States or Europe. TransConhGH has Orphan Drug designation for GHD in both the United States and Europe.
A potential approval of TransConhGH will enable the company to address the large unmet need and be a potential new treatment option forchildren with GHD.
Ascendis Pharma plans to submit a Marketing Authorization Application (MAA) for TransConhGH to the European Medicines Agency in the third quarter for pediatric GHD. The company also plans to initiate a phase III study with TransConhGH in pediatric GHD in Japan in the fourth quarter and a phase III study is ongoing in Greater China.
Shares of Ascendis have increased 6.4% year to date compared with the industry’s growth of 10.8%.
Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company which aims at making a meaningful difference in patients’ lives.
Zacks Rank &Stocks to Consider
Ascendis currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Applied Therapeutics Inc. (APLT - Free Report) , Emergent Biosolutions Inc. (EBS - Free Report) and Ligand Pharmaceuticals Inc. (LGND - Free Report) , all carrying a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Applied Therapeutics’ loss per share estimates have narrowed from $3.02 to $2.73 for 2020 and from $3.41 to $3.28 for 2021 in the past 60 days.
Emergent’s earnings per share estimates have increased from $3.43 to $4.03 for 2020 and from $3.54 to $3.73 for 2021 in the past 60 days.
Ligand Pharmaceuticals’ earnings per share estimates have increased from $3.45 to $3.70 for 2020 and from $4.00 to $4.40 for 2021 in the past 60 days.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>